**Dear Editor**,

More than 50 years have passed since the *myxovirus resistance* (*MX*) genes were first discovered and found to suppress infection with influenza viruses in mice (Lindenmann, [@CR10]). Like most mammals, mice carry two *MX* genes, *MX1* and *MX2*, which have arisen by gene duplication; both of these genes exhibit antiviral activity against a wide range of viruses (Liu et al., [@CR11]). Humans also have two *MX* genes, encoding the MxA and MxB proteins, which are interferon-induced, dynamin-like large molecular weight guanosine triphosphatases (GTPases). The antiviral functions of MxA have been deeply explored: MxA can protect cells from infection by multiple groups of pathogenic DNA and RNA viruses, such as influenza A virus and hepatitis B virus (Liu et al., [@CR11]). In contrast, Mx2, although closely related to MxA (63% amino acid \[aa\] sequence identity), appears to have lost its antiviral function and has been recognized as playing other cellular roles, since it does not suppress the viruses tested (Melen et al., [@CR12]).

Recently, Mx2 has been shown to serve as an inhibitor of human immunodeficiency virus type-1 (HIV-1) (Goujon et al., [@CR6]; Kane et al., [@CR9]; Liu et al., [@CR11]). Mx2 restricts HIV-1 infection at a relatively late post-entry phase (Goujon et al., [@CR6]; Kane et al., [@CR9]) and leads to a reduced level of integrated viral DNA (Liu et al., [@CR11]). The N-terminal 91-aa domain of Mx2 has been identified as a critical determinant of Mx2's antiviral activity (Busnadiego et al., [@CR1]). Interestingly, several mutations in the HIV-1 viral capsid (CA) region of Gag can overcome Mx2-mediated suppression (Goujon et al., [@CR6]; Kane et al., [@CR9]; Liu et al., [@CR11]). Thus, Mx2 may bind to the HIV-1 core and inhibit the early events in HIV-1 binding, thereby restricting viral infection. However, there is still no evidence showing that Mx2 directly binds to the HIV-1 capsid. Whether capsid binding of Mx2 requires cellular co-factors and/or higher-order assemblies of CA is also unknown. In this study, we have obtained a stable Mx2 protein containing the N-terminal 91-aa domain. Furthermore, we have observed that purified Mx2 recombinant proteins bind directly to HIV-1 CA assemblies *in vitro*. The N-terminal 83-aa domain of Mx2 is apparently critical for this interaction.

Human MxA and Mx2 share a similar aa sequence and domain architecture (Liu et al., [@CR11]; Melen et al., [@CR12]). The crystal structure of MxA indicates that it includes a G domain that binds and hydrolyzes GTP; a hinge-like "bundle signaling element (BSE)" that connects the G domain to the elongated stalk domain; and the stalk domain, which is involved in self-assembly and oligomerization (Gao et al., [@CR4]; Gao et al., [@CR5]) (Fig.[1](#Fig1){ref-type="fig"}A). A unique feature of Mx2 is that it exhibits a longer N-terminal domain, including an NLS (N-terminal 25 aa).Figure 1**Interactions of Mx2 variants with CA tubular assemblies**. (A) Binding of His-sumo-N-GF and N-GF to pre-assembled wild-type CA tubes. Binding reactions were analyzed by SDS-PAGE using CA tubular assemblies at 80 μmol/L or binding buffer alone, incubated with His-sumo-N-GF and N-GF (79 μmol/L). Samples of the reaction mixture before centrifugation (t), of the supernatant (s), and of the pellet (p) are detected alone. (B) Binding of Mx2 constructs to preassembled wild-type CA tubes. Binding reactions were the same as in (A). No binding of any Mx2 construct without the N-terminal 83-aa domain was found. (C) Cryo-EM images of pre-assembled wild-type CA tubes used in the Mx2-CA binding experiments

To identify the contribution of the diverse Mx2 domains to capsid binding, we generated and screened a series of deletion constructs of Mx2 with an N-terminal His-Sumo-tag (Fig. S1A) and characterized the expression, solubility, stability, and oligomerization behavior of these constructs (Table S1). We found that full-length Mx2 was difficult to obtain in *E. coli*. The expression levels of all the other deletion constructs (1--387, 1--413) were greatly reduced, but ∆1--83 exhibited a highly improved expression level (Fig. S1B), indicating that the N-terminal 83-aa domain of Mx2 may cause low expression and instability in solution (Table S1). Other deletion constructs (84--387, 84--413) without the N-terminal 83-aa domain showed high expression levels (Fig. S1B), but it exhibited poor solubility and stability (Fig. S1C), indicating that the completeness of BSE plays a significant role in maintaining the structure of the Mx2 constructs. Thus, we were unable to obtain stable constructs with the N-terminal 83-aa domain.

To overcome this problem, on the basis of previous reports (Chappie et al., [@CR2]) and the structure of MxA (Gao et al., [@CR5]), we engineered a minimal GTPase-BSE fusion protein (GF) that connected residues 84--413 and residues 683--715 from human Mx2 via a flexible linker (Fig. S1A). GF eluted as a monodispersed peak from a size-exclusion column and had much better solubility (\>20 mg/mL) than did residues 84--387 and 84--413 (Fig. S1C). In the next phase, we added the N-terminal 83-aa domain of Mx2 to GF in order to generate an N-terminal-GTPase-BSE fusion protein (N-GF). His-Sumo-N-GF showed a highly improved expression level (\>20 mg/L in *E. coli*) and solubility when compared to other deletion constructs with the N-terminal 83-aa domain (Fig. S1C). After removing the Sumo-tag, we saw a reduction in the stability of the N-GF proteins, but N-GF eluted as a monodispersed peak from a size-exclusion column (Table S1). Thus, we successfully generated a stable fusion construct of Mx2 for use in detecting further binding.

It had previously been demonstrated that assembled HIV-1 CA-NC tubular complexes can interact with full-length MX2 and its truncations containing the N-terminal 91-aa (isolated from HEK293T cell lysates) (Fricke et al., [@CR3]). To further clarify whether Mx2 directly binds to HIV-1 CA assemblies (at 20 μmol/L) *in vitro*, we tested purified His-Sumo-N-GF and N-GF (79 µmol/L) in precipitation assays with preassembled CA tubes. The results clearly indicated that the N-GF proteins co-pellet with assembled CA, revealing that the binding process does not require other cellular co-factors (Fig. [1](#Fig1){ref-type="fig"}A); thus, established that Mx2 directly binds to HIV-1 CA tubes *in vitro*.

We performed a further dissection of the interactions between the Mx2 constructs and CA to address the contribution of the different Mx2 domains to capsid binding. Purified GF, ∆1--83, and the stalk domain (79 μmol/L) were each tested in the precipitation assay with preassembled CA tubes (20 μmol/L). Essentially no binding was observed for GF, ∆1--83, or the stalk domain under the same assay conditions (Fig. [1](#Fig1){ref-type="fig"}B). All CA tubes were prepared as previously described (Yang et al., [@CR15]2012; Hung et al., [@CR8]) and were confirmed by cryo-electron microscopy (cryo-EM) (Fig. [1](#Fig1){ref-type="fig"}C). The findings described above indicate that Mx2-CA binding requires the N-terminal 83-aa of Mx2. The N-GF does not contain the stalk domain, but it is apparently sufficient to bind HIV-1 CA assembly. On the other hand, the stalk domain alone showed no binding to the assembled CA tubes (Fig. [1](#Fig1){ref-type="fig"}B).

HIV-1 capsid (CA) proteins can assemble into closed fullerene cones or helical tubes *in vivo* and *in vitro*. It is widely known that tripartite motif protein isoform 5 alpha (TRIM5α) is an antiviral protein that restricts infection of HIV-1 by binding to the viral capsid. The TRIM5α-CA binding interaction requires an assembled capsid lattice, since individual CA monomers do not have an appreciable affinity for TRIM5α (Stremlau et al., [@CR14]). It is the shape of the HIV-1 capsid that is recognized by the TRIM5α protein (Yang et al., [@CR15]). Having confirmed the binding of Mx2-CA assemblies, we wanted to investigate whether, like TRIM5α, Mx2 binds to the viral capsid by recognizing the shape of the higher-order assembled HIV-1 capsid lattice. Therefore, we over-expressed and purified individual hexamers (A14C/E45C/W184A/M185A), pentamers (A21C/E22C/W184A/M185A), and monomers of CA as previously described (Fig. [2](#Fig2){ref-type="fig"}A) (Pornillos et al., [@CR13]), and separately examined the binding affinity between each of them and GST-N-GF by GST pull-down assays, detecting the results by SDS-PAGE. No complex formation was detected, even at very high concentrations of both proteins (Fig. [2](#Fig2){ref-type="fig"}B). This result demonstrates that Mx2 shows no detectable binding to CA hexamers, pentamers, or monomers, implying that a higher-order lattice of CA tubes is required for an efficient Mx2-CA interaction.Figure 2**GST Pull-down assays of GST-N-GF with CA hexamers, pentamers, and monomers**. (A) Size-exclusion chromatographic profiles of individual CA hexamers, pentamers, and monomers. (B) Pull-down assays of GST-N-GF with CA hexamers, pentamers, and monomers. CA hexamers, pentamers, and monomers, incubated with GST-N-GF-bound glutathione-sepharose beads, showed no more interaction than those incubated with glutathione-sepharose beads alone

In the current study, we have demonstrated for the first time that a direct interaction occurs between Mx2 and the HIV-1 capsid. The N-terminal region of Mx2 is critical for this interaction. We identified a fusion protein of Mx2 containing the N-terminal 83-aa and the complete BSE (N-GF), which was fundamental for the detection of Mx2-CA binding *in vitro*. The N-GF construct may also facilitate further biochemical and structural studies of Mx2. The co-pelleting of purified N-GF and CA tubes, as well as domain mapping studies, showed that Mx2 directly recognizes CA assembles through its N-terminal 83-aa domain. Based on the results of pull-down assays, Mx2-CA binding requires the higher-order assembled capsid lattice, just as TRIM5α-CA binding does.

While this work was in progress, it was reported that assembled HIV-1 CA-NC tubular complexes can co-pellet Mx2 from whole-cell lysates (Fricke et al., [@CR3]). However, there is no evidence to show that Mx2 directly binds to CA *in vitro* (i.e., whether capsid binding of Mx2 requires co-factors in cells). The contribution of the NC domain to the binding of Mx2 to higher-order assemblies of CA-NC was also not clear. Our data argue that there is direct interaction between Mx2 and HIV-1 CA. Interestingly, several mutations in the HIV-1 viral capsid (CA) region of Gag can overcome MX2-mediated suppression (Fricke et al., [@CR3]; Liu et al., [@CR11]). The CA-NC tubular complexes that are formed with mutations in CA that help HIV-1 escape from Mx2 restriction exhibit weakened interactions with Mx2 (Fricke et al., [@CR3]). Thus, Mx2 may bind to the HIV-1 core and inhibit the process of HIV-1 infection.

It has been reported that Mx2 variants ∆572--715 and ∆623--715 have lost their ability to oligomerize, and they fail to bind to CA-NC assemblies *in vitro* (Fricke et al., [@CR3]). Our results show that although N-GF lacks the stalk domain involved in oligomerization, it still has the ability to bind CA tubes. This binding may occur because N-GF has the complete BSE, which is of great importance in maintaining normal Mx2 structure. These results suggest that although it is possible that the oligomerization of Mx2 produces a higher binding affinity for the viral capsid, oligomerization is not necessary for Mx2-CA binding. Future studies will be required to explore the oligomerization functions that are required for Mx2-mediated HIV-1 restriction (Haller et al., [@CR7]).
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